Europe Infection Control Companies and Market Trends and Growth
- Ecolab Inc.
- Diversey (Solenis / Diversey brand)
- STERIS plc
- Getinge AB
- 3M Company
- Becton, Dickinson and Company (BD)
- Mölnlycke Health Care AB
- Reckitt Benckiser Group plc (RB)
- Sotera Health / Sterigenics (Sotera group)
- Belimed AG
- Matachana Group
- MELAG Medizintechnik GmbH & Co. KG
- MMM Group (Müeller Medizinische Maschinen)
- PDI (Professional Disposables International)
- Metrex Research (Metrex)
- Clorox Healthcare (The Clorox Company)
- B. Braun Melsungen AG
- Cardinal Health
- Kimberly-Clark Professional
- Pal International Ltd.
Market Growth
The Europe infection control market size is estimated at US$ 14.17 billion in 2024, is projected to grow to US$ 15.1 billion in 2025, and is expected to reach around US$ 26.71 billion by 2034. The market is projected to expand at a CAGR of 6.54% between 2025 and 2034.
Europe Infection Control Market Trends
Increasing partnership and collaboration between government organizations and healthcare companies drives the growth of the market.
For instance,
- In May 2025, Active Citizenship Network, in partnership with RPP Group, launched a strategic initiative aimed at advancing respiratory care at the European Union level. The effort seeks to address the persistent lack of political attention given to respiratory diseases, despite their significant and growing impact on public health, particularly in the wake of the COVID-19 pandemic.
Increasing healthcare funding for the adoption of advanced technology for controlling infectious diseases, which contributes to the growth of the market.
For Instance,
- In July 2025, Ambitious EU funding for prevention and immunisation is crucial to reinforce Europe’s autonomy, biosecurity, economic stability, and long-term resilience. The European Union takes a continued step toward strengthening its competitiveness and health preparedness.
Europe Infection Control Market – Value Chain Analysis
R&D
Research and development of European infection control includes different processes, such as detection and diagnosis of the pathogen, as well as the collection of existing tools to treat and manage the infection and curtail AMR. Consistently develop knowledge and have products ready for scale-up and distribution.
Key players: STERIS plc., Getinge AB, Ecolab, Inc., and 3M Company
Clinical Trials
Clinical trials for infection control include different strategies for pre-employment screening of infection control consumables, including a questionnaire, targeted serological testing, and mass vaccination without testing or personalized vaccination.
Key players: Infection Control Teams (ICTs), Infection Preventionists (IPs), and Clinical Research Organizations (CROs)
Patient Support and Services
Infection control services are a useful, evidence-based approach that prevents patients and health care workers from being infected by avoidable infections. That includes maintaining the hygiene of hands, personal protective tools, suitable patient placement, and cleaning and disinfecting patient care devices.
Latest Announcements by Industry Leaders
In April 2025, David Shepherd, President & Chief Operating Officer, Advanced Wound Care at Convatec, stated, “ConvaNiox has significant potential for patients and healthcare professionals. Regulatory approval marks the beginning of what this novel technology can bring to the treatment of chronic conditions. ConvaNiox provides patients and medical care professionals renewed confidence by unlocking the potential of nitric oxide to treat a range of hard-to-heal wounds.”
Recent Developments in the Europe Infection Control Market
- On January 28, 2025, the PIPELINE project officially kicked off, a ground-breaking initiative aimed at enhancing preparedness and response to infections affecting pregnant people and infants in Europe. This collaborative effort brings together leading researchers, medical care professionals, and institutions from multiple countries, united by a shared commitment to enhancing health outcomes for these underserved populations.
- In April 2025, Convatec will launch ConvaNioxTM later this year, ahead of full launch in 2026. This new technology is powered by a potent antimicrobial1 2 and antibiofilm3 agent, nitric oxide, and is supported by strong clinical evidence. As ConvaNioxTM scales up, it will initially be available for the management of diabetic foot ulcers (DFUs), for which it has demonstrated outstanding clinical results4, reducing wound area three times faster and increasing DFU healing by 60%, compared to the standard of care, in a randomised controlled trial.
- In June 2025, the European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) officially launched. The initiative's goal is to bring together 53 organisations from 30 countries to combat the growing problem of antimicrobial resistance through research, networking, policy implementation, and public awareness.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
